Najda Jacek, Stella-Hołowiecka Beata, Machalski Marek, Woszczyk Dariusz, Mykała-Cieśla Joanna
Katedry i Kliniki Chorób Wewnetrznych i Chemioterapii Onkologicznej, Slaskiej Akademii Medycznej w Katowicach.
Wiad Lek. 2002;55(9-10):600-7.
Wilson's disease defined also as hepatolenticular degeneration is an important clinical problem of young adults still causing diagnostic difficulties. In the course of the last decade, genetic background of the disease has been definitely established and elucidated, confirming the variety of genetic mutations, responsible for its origin. The current scheme of the disease treatment has been elaborated and established. It aims to eliminate the excess of toxic copper ions from the organism as fast as possible. In the initial phase of the treatment, traditional and recently introduced chelating agents administration usually results in prompt tissue copper deposits excretion and copper metabolism balance maintenance. In the chronic therapy, zinc compounds, inducing intestinal and hepatic metallothionein synthesis, have been gaining more common application. Life-long, constant, pharmacological Wilson's disease therapy, administered after its early diagnosis, allows for long periods of patients survival, frequently comparable to the normal population.
威尔逊氏病也被定义为肝豆状核变性,是年轻成年人面临的一个重要临床问题,至今仍存在诊断困难。在过去十年中,该疾病的遗传背景已得到明确确立和阐释,证实了导致其发病的多种基因突变。目前已制定并确立了该疾病的治疗方案。其目的是尽快从机体中清除过量的有毒铜离子。在治疗的初始阶段,使用传统的以及最近引入的螯合剂通常会促使组织中铜沉积物迅速排出,并维持铜代谢平衡。在慢性治疗中,能诱导肠道和肝脏金属硫蛋白合成的锌化合物得到了更广泛的应用。在早期诊断后进行终身持续的威尔逊氏病药物治疗,可使患者长期存活,其存活期通常与正常人群相当。